* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Inhibition of cyclooxygenase-2 improves cardiac - AJP
Survey
Document related concepts
Remote ischemic conditioning wikipedia , lookup
Heart failure wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Coronary artery disease wikipedia , lookup
Electrocardiography wikipedia , lookup
Echocardiography wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Cardiothoracic surgery wikipedia , lookup
Cardiac surgery wikipedia , lookup
Heart arrhythmia wikipedia , lookup
Transcript
Am J Physiol Heart Circ Physiol 286: H1416–H1424, 2004; 10.1152/ajpheart.00136.2003. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse Margot C. LaPointe, Mariela Mendez, Alicia Leung, Zhenyin Tao, and Xiao-Ping Yang Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, Michigan 48202 Submitted 13 February 2003; accepted in final form 5 December 2003 echocardiography; NS-398; collagen; nonsteroidal anti-inflammatory drugs; prostanoids CYCLOOXYGENASE (COX), also known as prostaglandin endoperoxide H synthase, exists as two isoforms, COX-1 and COX-2 (43). COX-1 is expressed in almost all tissues, and its prostanoid products are thought to mediate physiological responses such as vascular homeostasis and protection of the gastric mucosa. Although COX-2 products are generally considered inflammatory mediators and thus deleterious, they can exhibit both beneficial and deleterious effects in the same tissue, for example, the kidney (14, 44). In addition to inflammation, COX-2 products have been associated with regulation of cell proliferation, in particular colon cancer (12, 45). Pros- Address for reprint requests and other correspondence: M. C. LaPointe, Hypertension and Vascular Research Division, Henry Ford Hospital, 2799 West Grand Blvd., Detroit, MI 48202-2689 (E-mail: [email protected]). H1416 tanoids produced by COX-2 affect a number of other biological processes, including angiogenesis, differentiation, and apoptosis (24, 46). HEK-293 cells overexpressing both COX-2 and PGE2 synthase release large quantities of PGE2, grow faster than normal cells, and also exhibit altered morphology (30). In addition, COX-2 has been detected in the heart in patients with congestive heart failure and during allograft rejection (47, 50). However, we know very little about its regulation in the heart or its contribution to cardiac structure and function. COX-1 and -2 catalyze conversion of arachidonic acid to the prostaglandin endoperoxide PGH2 by similar mechanisms. Arachidonic acid released by proinflammatory stimuli tends to be preferentially utilized by COX-2, and when COX-2 and COX-1 are functional in the same cell, COX-2 can form up to four times as much PGH2 as COX-1 (40). PGH2 is converted to a variety of prostanoids including PGE2, PGI2, PGF2␣, PGD2, and thromboxane A2 by specific synthases (12, 46), and a specific synthase seems to be functionally coupled to either COX-1 or -2 within the cell to produce a particular prostanoid. For example, COX-2 and inducible PGE2 synthase (PGES) are coupled to generate PGE2 in the inflammatory response (30). We have previously shown that the cytokine IL-1 induces both COX-2 and PGES in neonatal ventricular myocytes and that PGE2 and PGF2␣, but not a PGI2 analog, stimulate hypertrophic growth of myocytes (27). In contrast to hormones, which have broad systemic effects, prostanoids serve as intracrine, autocrine, and paracrine mediators, signaling changes within the immediate environment. Upregulation of COX in the heart could produce prostanoid products that would affect cell function. Previous studies examining the role of COX in the heart used nonselective COX inhibitors, and these studies produced variable results (4, 6, 18, 29). In recent studies in rodents, COX-2 selective inhibitors were given before myocardial infarction (MI) and resulted in decreased fibroblast proliferation and improved cardiac function (36, 38). However, the studies did not distinguish between the effects of COX-2 inhibitors on wound healing and scar formation as well as subsequent remodeling. In an attempt to clarify some of the processes regulated by COX-2 in the heart, we studied the effects of administering a COX-2 inhibitor 48 h post-MI and for an additional 2 wk on cardiac function, fibrosis, and hypertrophy. METHODS Animal Procedures Male C57BL/6J mice from Jackson Laboratories were housed in a temperature-controlled room with a 12:12-h light-dark cycle and given standard chow and tap water. They were housed for at least 1 wk before the start of the experiment, which was approved by the The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 0363-6135/04 $5.00 Copyright © 2004 the American Physiological Society http://www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.32.247 on May 10, 2017 LaPointe, Margot C., Mariela Mendez, Alicia Leung, Zhenyin Tao, and Xiao-Ping Yang. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 286: H1416–H1424, 2004; 10.1152/ ajpheart.00136.2003.—Cyclooxygenase (COX)-2 is expressed in the heart in animal models of ischemic injury. Recent studies have suggested that COX-2 products are involved in inflammatory cell infiltration and fibroblast proliferation in the heart. Using a mouse model, we questioned whether 1) myocardial infarction (MI) in vivo induces COX-2 expression chronically, and 2) COX-2 inhibition reduces collagen content and improves cardiac function in mice with MI. MI was produced by ligation of the left anterior descending coronary artery in mice. Two days later, mice were treated with 3 mg/kg NS-398, a selective COX-2 inhibitor, or vehicle in drinking water for 2 wk. After the treatment period, mice were subjected to two-dimensional M-mode echocardiography to determine cardiac function. Hearts were then analyzed for determination of infarct size, interstitial collagen content, brain natriuretic peptide (BNP) mRNA, myocyte cross-sectional area, and immunohistochemical staining for transforming growth factor (TGF)- and COX-2. COX-2 protein, detected by immunohistochemistry, was increased in MI versus sham hearts. MI resulted in increased left ventricular systolic and diastolic dimension and decreased ejection fraction, fractional shortening, and cardiac output. NS-398 treatment partly reversed these detrimental changes. Myocyte cross-sectional area, a measure of hypertrophy, was decreased by 30% in the NS-398 versus vehicle group, but there was no effect on BNP mRNA. The interstitial collagen fraction increased from 5.4 ⫾ 0.4% in sham hearts to 10.4 ⫾ 0.9% in MI hearts and was decreased to 7.9 ⫾ 0.6% in NS-398-treated hearts. A second COX-2 inhibitor, rofecoxib (MK-0966), also decreased myocyte cross-sectional area and interstitial collagen fraction. TGF-, a key regulator of collagen synthesis, was increased in MI hearts. NS-398 treatment reduced TGF- immunostaining by 40%. NS-398 treatment had no effect on infarct size. These results suggest that COX-2 products contribute to cardiac remodeling and functional deficits after MI. Thus selected inhibition of COX-2 may be a therapeutic target for reducing myocyte damage after MI. COX-2 AND CARDIAC REMODELING Henry Ford Hospital Institutional Animal Care and Use Committee. Mice were ⬃12 wk of age (24–30 g) when they underwent surgery. To induce MI, mice were anesthetized with pentobarbital sodium (50 mg/kg ip), and a left thoracotomy was performed. The left anterior descending coronary artery (LAD) was ligated with an 8-0 silk suture placed near its origin at the edge of the left atrium as described previously (15). Ligation was deemed successful when the anterior wall of the left ventricle (LV) turned pale. The ligature was positioned so as to produce a moderate infarct (30–45%). Sham operation was identical except that the ligature was placed and then removed without tightening it. Mice were kept on a heating pad and monitored until awake. The MI surgical procedure resulted in 12% mortality. Experimental Protocols AJP-Heart Circ Physiol • VOL Echocardiography Two-dimensional M-mode transthoracic echocardiography was performed on conscious mice using an Acuson 256 system (Mountain View, CA) with a 15-MHz linear transducer as reported previously (15). M-mode images were used to determine LV end-diastolic dimension (LVDd) and LV end-systolic dimension (LVDs). Diastolic measurements were made at the maximum LV cavitary dimension, whereas systolic parameters were measured during maximum anterior motion of the posterior wall. Infarct Size IS was measured as described previously (51). For each heart, 6-m sections from each of the three slices of sections A, B, and D were stained with Gomori trichome to identify fibrous tissue (infarction). IS was calculated as the ratio of infarct length to the circumference of both the endocardium and epicardium. Measurement of ICF and MCSA Slices from sections A, B, and D of the heart were double stained with fluorescein-labeled peanut agglutinin to delineate the MCSA and interstitial space and rhodamine-labeled Griffonia simplicifolia lectin I to outline the capillaries (22). Four radially oriented microscope fields were selected from each section, two adjacent to the infarct (border zone) and two away from it, and photographed at a magnification of ⫻100. MCSA was measured by computer-based planimetry (Jandel) and averaged across all four fields of the sections from the three slices. To determine ICF, the total surface area (microscope field), interstitial space (collagen plus capillaries), and the area occupied by capillaries alone were measured with videodensitometry (SigmaScan, Jandel). ICF was calculated as the total surface area occupied by the interstitial space minus the percentage of total surface area occupied by the capillaries. Detection of COX-2 and TGF- by Immunostaining Frozen sections (6 m) of section B of the heart were fixed with acetone for 10 min and rinsed in PBS. Tissue sections were preincubated with 0.3% hydrogen peroxide in PBS to inhibit endogenous peroxidase activity. They were then washed twice in PBS for 5 min each time, preincubated with blocking serum (5% normal serum) for 30 min, and then incubated with the primary antibody at 4°C overnight. For COX-2 immunostaining, sections were incubated with a 1:500 dilution of COX-2 antibody (M-19, Santa Cruz Biotechnology). For detection of TGF-, a 1:500 dilution of monoclonal antibody was used (MAB 1835, R&D Systems). After sections were washed with PBS, species-appropriate biotinylated secondary antibodies were applied, followed by avidin-peroxidase complexes (Vector Laboratories). 3-Amino-9-ethyl carbazole was used as the substrate (Vector Laboratories), and slides were counterstained with Gill’s hematoxylin solution. For quantitation of TGF- staining, two fields enclosing the infarct border were photographed using a Nikon microscope attached to a digital camera. The image was obtained using SPOT software (version 3.4.2, Diagnostic Instruments) at ⫻400 magnification. The area that stained positive for TGF- was expressed as a percentage of the total myocardial area. All slides were evaluated in blinded fashion. Analysis of Brain Natriuretic Peptide and COX-2 mRNA by Real-Time PCR Total RNA was extracted by homogenization of myocardial samples in Tri-Reagent (Molecular Research Center; Cincinnati, OH) following the manufacturer’s instructions. For brain natriuretic peptide (BNP) mRNA, the section of the mouse heart homogenized included a portion of the noninfarcted LV free wall and the septum (section C from protocol 2). For COX-2 mRNA, the LV was divided into infarcted and noninfarcted regions, which were extracted sepa- 286 • APRIL 2004 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.32.247 on May 10, 2017 Protocol 1: effect of NS-398 on cardiac PGE2. Mice were subjected to MI to document an increase in cardiac COX-2 and PGE2 and to test the ability of NS-398 (NS) to inhibit COX-2-derived PGE2. After 24 h, the LV was divided into infarcted and noninfarcted regions, and RNA was isolated for real-time RT-PCR analysis of COX-2 mRNA. A second group of mice was subjected to MI, and, after 24 h, hearts were extracted for determination of PGE2 levels. To insure that NS inhibited MI-induced PGE2, a third group of MI mice was treated three times with 3 mg/kg NS (on the day before surgery, 2 h before surgery, and 2 h before death). Twenty-four hours after surgery, hearts were removed and extracted for PGE2 analysis. Hearts were homogenized in 1 ml of methanol containing 10 g/ml indomethacin. The volume of methanol was adjusted to 4 ml, and PGE2 was extracted by repeated vortexing over a 30-min period. After centrifugation at 4,500 rpm at 4°C, the supernatant was purified through PGE2 affinity columns according to the manufacturer’s instructions (Cayman Chemicals; Ann Arbor, MI). After the sample was eluted from the column, the sample was dried in a Savant and then resuspended in 0.4 ml assay buffer. One-half of the sample was frozen, whereas the other half was analyzed for PGE2 with an enzyme-linked immunoassay kit from Cayman Chemicals according to the manufacturer’s protocol. Results were recorded as picograms per sample. PGE2 (200 pg) was added to an affinity column to measure recovery. Recovery of PGE2 from the columns averaged ⬎95%. Protocol 2: effect of NS on cardiac structure and function. Mice with MI were divided into two groups and started on 3 mg䡠kg⫺1 䡠day⫺1 NS (Cayman Chemicals) or vehicle in drinking water 48 h after MI and lasting for 2 wk. Sham-operated mice received tap water. In the first 5–6 days of treatment, there was no apparent difference in survival of vehicle-treated and NS-treated mice. After the treatment period, mice were subjected to two-dimensional M-mode echocardiography to determine cardiac function, and mice were then euthanized. Hearts were removed and sectioned transversely into four slices from apex to base. Three of the sections (sections A, B, and D) were frozen in isopentane and stored at ⫺70°C for determination of infarct size (IS), interstitial collagen fraction (ICF), myocyte cross-sectional area (MCSA), and immunohistochemical staining for transforming growth factor (TGF)- and COX-2. The fourth section (section C) was stored in RNALater (Ambion) at ⫺70°C for subsequent extraction of RNA. Section A contained mostly infarcted tissue, and section B was adjacent to the infarct, whereas sections C and D contained noninfarcted myocardium. Protocol 3: effect of rofecoxib on MCSA and ICF. To verify the histopathology studies described in protocol 2, we tested a second COX-2 inhibitor, rofecoxib (MK-0966; kindly provided by Dr. Robert Young, Merck Frosst, Quebec, Canada). The drug was administered in chow [0.0075% rofecoxib (wt/wt) in chow ⫽ 15 mg䡠kg⫺1 䡠day⫺1] beginning 2 days after MI and continuing for 2 wk. Plasma samples from 11 mice fed this dose for 2 wk gave rofecoxib values of 109 ⫾ 16 ng/ml, consistent with therapeutic levels in humans (values kindly determined by Pauline Luk, Merck Frosst, Quebec, Canada). H1417 H1418 COX-2 AND CARDIAC REMODELING Statistical Analysis Data were tested for normality and equality of variance and adjusted appropriately. If the data were not normally distributed, then the nonparametric Wilcoxon rank-sum method was used. The Satterthwaite adjustment was used for data with unequal variances. BNP mRNA data were analyzed by the nonparametric Wilcoxon rank-sum method. All other data are expressed as means ⫾ SE and were analyzed by t-test or one-way ANOVA, with multiple pairwise comparisons made by the Student-Newman-Keuls method. TGF- data were analyzed by t-test with the Satterthwaite adjustment for unequal variances. P ⬍ 0.05 was considered significant. RESULTS Effect of MI on COX-2 and PGE2 in the Heart To test the acute effect of MI on COX-2 mRNA and PGE2 levels in the heart, we analyzed total RNA from the infarcted and noninfarcted regions of the LV free wall 24 h post-MI. COX-2 mRNA normalized to -actin mRNA was increased 4.4-fold in the infarcted LV (Fig. 1A). Cardiac PGE2 levels were increased 3.7-fold after MI (Fig. 1B). Doses of NS ranging from 1 to 10 mg䡠kg⫺1 䡠day⫺1 have been shown to be efficacious in several different models (13, 25, 37, 39). PGE2 in sham hearts was 6.9 pg/sample (n ⫽ 8), which increased to 26.52 pg/sample (n ⫽ 12) in MI hearts. Treatment of mice with 3 mg䡠kg⫺1 䡠day⫺1 NS reduced cardiac PGE2 levels to 12.5 pg/sample (n ⫽ 9) (Fig. 1B). As a control for the PGE2 assay, we used indomethacin (10 mg/kg), a COX-1/ COX-2 inhibitor, and found that PGE2 was decreased to levels below the lower limit of detection of the assay. To study chronic induction of COX-2 in MI hearts, we stained sections of hearts from a separate group of animals for COX-2 immunoreactivity. Part of section B (adjacent to the infarct) from sham and MI hearts was immunostained using a polyclonal COX-2 antibody. Sections from sham hearts showed no staining, but sections from the heart 16 days post-MI showed very intense localized brown staining in the myocytes (Fig. 2). Effect of COX-2 Inhibition on Cardiac Function We used two-dimensional M-mode echocardiography to evaluate cardiac function in untreated and NS-treated mice. Ejection fraction, shortening fraction, stroke volume, and cardiac output decreased in MI versus sham mice (Fig. 3). In all cases, COX-2 inhibition partly reversed the detrimental effects of MI. COX-2 inhibition had no effect on heart rate (data not shown). MI also increased both LVDs and LVDd (Fig. 4, A and B). COX-2 inhibition significantly reduced LVDs (P ⬍ 0.01) and tended to reduce LVDd (P ⫽ 0.09, NS-treated MI mice versus vehicle-treated MI mice). Effect of COX-2 Inhibition on Hypertrophy and Fibrosis Using the heart sections, we next measured MCSA as an index of hypertrophy. MCSA increased 2-fold in MI versus sham hearts, and COX-2 inhibition reduced this to 1.7-fold (sham: 149 m2, MI: 302 m2, MI ⫹ NS: 257 m2; P ⬍ 0.05, MI vs. NS; Fig. 5A). Because increases in the expression of Fig. 1. Analysis of cyclooxygenase (COX)-2 mRNA and cardiac PGE2. A: COX-2 mRNA was evaluated in the infarcted (INF) and noninfarcted (non-INF) regions of the left ventricle (LV) and normalized to -actin mRNA; n ⫽ 4 for both bars. B: PGE2 was extracted from sham or myocardial infarcted (MI) hearts and expressed as picograms per sample; n ⫽ 8 for sham; n ⫽ 12 for MI; n ⫽ 9 for MI/NS-398 (NS); n ⫽ 7 for MI/indomethacin (Indo). ND, not detectable. Statistical significance is indicated in the graph. The values for sham versus MI/NS were not statistically different. AJP-Heart Circ Physiol • VOL 286 • APRIL 2004 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.32.247 on May 10, 2017 rately. At the end of the procedure, samples were treated with DNAse I from Ambion’s RNAqueous-4PCR kit. RT was performed using the reagents of the Omniscript RT kit (Qiagen) with 2 g total RNA, 1 g random primer (Invitrogen), and 10 U/l RNAsin (Promega) in a 20-l volume for 1 h at 37°C. Real-time PCR was performed using the QuantiTect Probe PCR kit (Qiagen) and a Roche LightCycler (version 3.5). Fluorescence resonance energy transfer probes and primers were designed by TIB MolBiol (Adelphia, NJ). Data analysis was performed with LightCycler software (version 3.5.28). The reaction volume was 20 l and contained 2 l cDNA, 0.5 M sense and antisense primers, 0.2 M each of the LC-640 red-labeled and fluorescein-labeled probes, Taq polymerase, and dNTPs for 45 cycles. For analysis of BNP (241 bp) and -actin (342 bp) cDNAs, PCR conditions were as follows: 0 s at 95°C for denaturation, 40 s at 58°C for annealing, and 40 s at 72°C for extension. For COX-2 (448 bp), PCR conditions were as follows: 0 s at 95°C for denaturation, 45 s at 58°C for annealing, and 90 s at 72°C for extension. The sequences of the primers/probes were as follows: BNP sense, 5⬘-ATGGATCTCCTGAAGGTGCTG-3⬘; BNP antisense, 5⬘-GTGCTGCCTTGAGACCGAA-3⬘; BNP fluorescein probe, 5⬘TGGCTAGGACTTCCCAGAGGATAGG-x-3⬘; BNP LC-640 probe, 5⬘-LC red 640-TGACCTCCCAGCGGTGACAGATAAA-p-3⬘; -actin sense, 5⬘-ACCCACACTGTGCCCATCTA-3⬘; -actin antisense, 5⬘-GCCACAGGATTCCATACCCA-3⬘; -actin fluorescein probe, 5⬘-GCCACGCTCGGTCAGGATCTTCAT-x-3⬘; -actin LC-705 probe, 5⬘-LC red 705-AGGTAGTCTGTCAGGTCCCGGCCA-p-3⬘; COX-2 sense, 5⬘-GTGACTGTACCCGGACTGGAT-3⬘; COX-2 antisense, 5⬘-AAGTGCTGGGCAAAGAATGC-3⬘; COX-2 fluorescein probe, 5⬘-CTGGGAAGCCTTCTCCAACCTCTCC-x-3⬘; and COX-2 LC-640 probe, 5⬘-ACTACACCAGGGCCCTTCCTCCC-p3⬘. Gene-specific standard curves were generated using a linearized plasmid containing the cDNA of interest and serially diluting it to generate concentrations ranging over two to four orders of magnitude. The LightCycler software calculated the amount of cDNA in a given sample (copies/l) compared with the standard curve. BNP and COX-2 mRNA were normalized to -actin mRNA. H1419 COX-2 AND CARDIAC REMODELING atrial natriuretic peptide and BNP genes are markers of hypertrophy, we used real-time PCR to quantitate changes in BNP gene expression in sham, MI, and NS-treated mouse hearts. There was a 3.6-fold increase in BNP mRNA in MI versus sham hearts, but COX-2 inhibition had no significant effect on BNP mRNA (Fig. 5B). We measured changes in ICF in sections from sham, MI, and MI ⫹ NS hearts as a measure of collagen in noninfarcted areas of the heart. The ICF of sham hearts was 5.4% and increased twofold to 10.4% in MI hearts (Fig. 6). In NS-treated hearts, ICF was decreased by 50% to 7.9%, indicating decreased collagen production (P ⬍ 0.05, MI vs. NS treated). To confirm the MCSA and ICF data, studies were repeated using a second COX-2 inhibitor, rofecoxib (MK-0966 or Vioxx). Treatment with rofecoxib for 2 wk decreased MCSA (Fig. 7A) and ICF (Fig. 7B) by 65% and 48%, respectively. Additionally, if mice were treated for 4 wk beginning 2 wk after MI, MCSA and ICF were similarly decreased (Fig. 7, C and D). Effect of COX-2 Inhibition on TGF- After MI, there is a sequential infiltration of the heart by inflammatory cells, such as neutrophils, macrophages, and lymphocytes (49), which contribute to removal of necrotic tissue, scar formation, and interstitial fibrosis. TGF-, which is synthesized and released by macrophages and fibroblasts, results in fibroblast proliferation and collagen synthesis (for a review, see Ref. 23). We examined slices of section B of the heart (adjacent to the scar) for TGF- (Fig. 8A) and quantified the immunostained area as a percentage of the entire section examined. TGF- staining increased from 0.4% in sham hearts Fig. 3. Effect of NS on cardiac function as measured by two-dimensional (2-D) M-mode echocardiography. A: ejection fraction (EF); B: shortening fraction (SF); C: cardiac output (CO); D: stroke volume (SV). Sham (n ⫽ 8) ⫽ sham operation; MI/Cont (n ⫽ 9) ⫽ vehicletreated MI mice; MI/NS (n ⫽ 8) ⫽ NS-treated MI mice. AJP-Heart Circ Physiol • VOL 286 • APRIL 2004 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.32.247 on May 10, 2017 Fig. 2. Immunohistochemical detection of COX-2 in the mouse heart post-MI. A: absence of specific staining in the sham heart. The reddish-brown staining in B demonstrates the presence of COX-2. Magnification ⫻400. The micrographs are representative of results from 8 sections of sham and MI hearts. H1420 COX-2 AND CARDIAC REMODELING Fig. 4. Effect of NS on LV shape as measured by 2-D M-mode echocardiography. A: LV systolic dimension (LVDs). B: LV diastolic dimension (LVDd) in sham (n ⫽ 8), MI/Cont (n ⫽ 9), and MI/NS mice (n ⫽ 8). Effect of COX-2 Inhibition on IS To test whether the cardioprotective effects of COX-2 inhibition were due to a decrease in IS, we measured IS in tissue sections from MI hearts treated with vehicle and MI hearts treated with NS. We found that IS as a percentage of the entire LV was unchanged by COX-2 inhibition [IS in the MI/vehicle group ⫽ 40 ⫾ 3% (n ⫽ 9) and in the MI/NS group ⫽ 37 ⫾ 4% (n ⫽ 8)]. The same was true for rofecoxib treatment [IS in the MI/vehicle group ⫽ 37.1 ⫾ 1.5% (n ⫽ 12) and in the MI/rofecoxib group ⫽ 37.8 ⫾ 1.6% (n ⫽ 12)]. DISCUSSION As an early inflammatory response gene, COX-2 is induced by a variety of stimuli. In the myocardium it is stimulated by cardiac allograft rejection (50) and MI (38) as well as during the development of heart failure (47). Our data show that 1) MI induced COX-2 in the mouse heart, 2) COX-2 inhibition with NS improved cardiac function, and 3) both NS and rofecoxib reduced MCSA and interstitial collagen. These data thus implicate COX-2 products in cardiac dysfunction after MI. Induction of COX-2 by injury has also been reported in other tissues. COX-2 expression was induced in the brain in different models of injury (11, 17, 19, 31), and inhibition of COX-2 by NS or gene knockout improved function after injury (17, 31). In mice, LAD ligation causes ischemia of the LV free wall and necrosis of infarcted tissue, followed by scar formation and remodeling of the noninfarcted myocardium. In this mouse model, LAD ligation results in rapid increases in LVDs and LVDd and decreased ejection fraction and cardiac output (51). We found that COX-2 inhibition with NS improved cardiac function, as evidenced by increased ejection fraction, shortening fraction, cardiac output, and stroke volume versus untreated mice. It is likely that the increases in ejection fraction and shortening fraction were due to improved cardiac contractility, because LVDd was not changed, whereas LVDs decreased significantly. Two other reports have focused on the role of COX-2 in the heart post-MI, but in both studies the COX-2 inhibitor was given before MI. Scheuren et al. (38) treated female rats with rofecoxib one day before MI and then for 4 days afterward. Their acute studies revealed decreased infiltration of inflammatory cells and decreased fibroblast proliferation and invasion of the infarct border. No functional studies were done, and no conclusions were drawn concerning the potential beneficial or deleterious effects of the acute reduction in inflammatory processes. In contrast, Saito et al. (36) administered the COX-2 selective inhibitor 5,5-dimethyl3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2 (5H)-furanone to male rats 30 min before MI and continued treatment for 2 wk. After another 2 wk, hemodynamic studies indicated that COX-2 inhibition reduced LV end-diastolic pressure and improved cardiac compliance, resulting in an overall increase in cardiac function. This supports our finding of an improvement in LVDs subsequent to NS treatment. Our studies also indicate that COX-2 inhibition reduced collagen deposition in the heart after MI. This beneficial alteration in the remodeling process probably reduced cardiac stiffness, thus accounting for the improved cardiac function. The decrease in collagen likely resulted from decreased TGF- release by either macrophages, myocytes, or fibroblasts, as we detected less TGF- immunostaining in NS-treated hearts. Our result is consistent with reports using two different models of renal injury in the rat. In these studies, chronic COX-2 inhibition reduced the extracellular matrix, TGF- production, glomerular injury, and proteinuria, thus improving renal function (8, 44). Fig. 5. Effect of NS on cardiac hypertrophy. A: myocyte cross-sectional area (MCSA); n ⫽ 8 sham, 9 MI/Cont, and 8 MI/NS mice. B: brain natriuretic peptide (BNP) mRNA (copies/l) as determined by real-time PCR and normalized to -actin in sham (n ⫽ 6), MI/Cont (n ⫽ 6), and MI/NS mice (n ⫽ 8). The difference between MI/NS and MI/vehicle for BNP mRNA was not statistically significant as determined by the nonparametric Wilcoxon rank-sum method. AJP-Heart Circ Physiol • VOL 286 • APRIL 2004 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.32.247 on May 10, 2017 to 1.2% in MI hearts and decreased by 50% to 0.7% in response to COX-2 inhibition by NS (Fig. 8B). COX-2 AND CARDIAC REMODELING The decrease in collagen content in our study most likely resulted from decreased proliferation of fibroblasts and decreased infiltration of inflammatory cells, which synthesize and release cytokines and growth factors involved in extracellular matrix formation. This was demonstrated by Scheuren et al. (38), who noted decreased numbers of macrophages and fibroblasts around the infarct area of rofecoxib-treated rats. Preliminary data from our laboratory suggest that the PGE2 analog sulprostone and PGF2␣ increase fibroblast proliferation in vitro (M. Mendez and M. C. LaPointe, unpublished observations). In addition to affecting fibroblast proliferation, prostanoids could participate in the acute inflammatory response by upregulation of the adhesion molecules necessary for infiltration and activation of neutrophils. The prostanoid PGF2␣ has been shown to stimulate ICAM-1 expression in gingival fibroblasts (32). COX-2 inhibitors have also been shown to decrease plasma levels of lipid peroxides, reduce cytokine release and/or action, and decrease production of superoxide anions by neutrophils (2, 3, 41). Thus the effect of COX-2 inhibition in reducing collagen production could result from a combination of direct effects on cardiac prostanoid formation, which would influence neutrophil and macrophage infiltration, fibroblast proliferation, and TGF- and collagen synthesis. COX-2 inhibition also reduced cardiac hypertrophy, as determined by measurements of MCSA. It has been reported that the nonsteroidal anti-inflammatory drug fenbufen prevented cardiac hypertrophy induced by clenbuterol in rats (35). Enhanced COX-2 expression in the heart would increase prostanoid production. We have previously shown that PGE2 acting through the EP receptor subtype EP4 stimulates hypertrophy of cardiac myocytes in vitro (27). The presence of EP4 receptors in the heart would allow locally produced PGE2 to induce hypertrophy of myocytes. Other prostanoids, including PGF2␣ and thromboxane A2, can also stimulate hypertrophy (1, 20, 27) as well as stimulate BNP expression (M. C. LaPointe, unpublished observations). BNP mRNA, a marker of hypertrophy and LV dysfunction, was induced by MI, but its levels were unchanged by COX-2 Fig. 7. Effect of 2- and 4-wk rofecoxib [MK-0966 (MK)] treatment on MCSA and ICF; n ⫽ 6 for each bar. A: MCSA after 2-wk treatment; B: ICF after 2-wk treatment; C: MCSA after 4-wk treatment; D: ICF after 4-wk treatment. Statistical significance is noted in the graph. AJP-Heart Circ Physiol • VOL 286 • APRIL 2004 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.32.247 on May 10, 2017 Fig. 6. Effect of NS on interstitial collagen fraction (ICF) in sham (n ⫽ 8), MI/Cont (n ⫽ 9), and MI/NS mice (n ⫽ 8). Statistical significance is noted in the graph. H1421 H1422 COX-2 AND CARDIAC REMODELING inhibition. The uncoupling of BNP expression from regression of hypertrophy has been previously reported. Using a model of suprarenal aortic banding, Ogawa et al. (33) demonstrated that when both hypertrophy and blood pressure were decreased by high-dose ramipril (an angiotensin-converting enzyme inhibitor), LV BNP mRNA was reduced. However, when hypertrophy was regressed without decreased blood pressure by lowdose ramipril, LV BNP mRNA remained elevated. Given that BNP decreases collagen synthesis and increases matrix metalloproteinase in fibroblasts in vitro (42), its continued synthesis in vivo might counter collagen accumulation in the setting of COX-2 inhibition. We found that COX-2 inhibition with either NS or rofecoxib (MK-0966) beginning 2 days post-MI had no effect on IS measured 14 days later. Scheuren et al. (38) also found that rofecoxib did not influence IS acutely in the rat. Although we did not detect any changes in overall IS in our study, we cannot exclude the possibility that COX-2 inhibition affected wound repair by altering infarct expansion or infarct thinning. A decrease in collagen in the scar per se could predispose the heart to rupture. Future studies will examine COX-2 inhibition in the chronic phases of remodeling so as to avoid potential effects on wound healing. There is some controversy regarding the role of COX-2 in the heart post-MI. Recent studies have indicated that rofecoxib may increase the risk of cardiovascular events in patients (5, 28). Cheng et al. (9) demonstrated that the vasodilator PGI2 is critical to oppose the actions of platelet thromboxane A2, and McAdam et al. (26) indicated that COX-2 is important for systemic synthesis of PGI2. If COX-2 is important for production of PGI2 in the vessel wall, then COX-2 inhibition might AJP-Heart Circ Physiol • VOL favor thrombosis. On the other hand, several studies have implicated COX-2 and its products in cardiovascular disease. Chenevard et al. (7) found that the COX-2 inhibitor celecoxib improved flow-mediated dilatation and decreased markers of inflammation and oxidative stress in male patients with severe coronary artery disease. COX-2 overexpression has also been associated with atherosclerotic plaque instability, which would lead to acute ischemic syndromes (10). Moreover, COX-2 expression is strongly induced during LPS-induced septicemia in rats, and treatment with the COX-2 inhibitor rofecoxib reversed the effects of LPS on systolic arterial pressure and heart rate as well as liver damage (16). It has also been shown that COX-2 is involved in the inflammatory process after MI. COX-2 inhibition reduced macrophage infiltration into the necrotic area and border zone of the infarcted rat heart as well as fibroblast proliferation (38, 48). Thus additional studies will be required to evaluate whether COX-2 inhibitors as a class have prothrombotic properties under certain circumstances, or if there are specific properties of the different COX-2 inhibitors that render them prothrombotic, as well as determine the different effects of COX-2 and prostanoid production on myocyte, fibroblast, and endothelial cell function. Because different cell types in the heart, e.g., myocytes, fibroblasts, and endothelial cells, produce different prostanoid profiles (21, 27, 34), the effect of induction of COX-2 will depend on the cell in which it is expressed, the prostanoids produced, and the ability of surrounding cells to respond to the prostanoids. In summary, our findings suggest that COX-2 plays a deleterious role in the heart after MI caused by chronic LAD occlusion. MI induces COX-2, with concomitant increases in PGE2, collagen content, and hypertrophy, and decreases in 286 • APRIL 2004 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.32.247 on May 10, 2017 Fig. 8. Effect of NS on transforming growth factor (TGF)- immunostaining. A: sham heart (a), peri-infarct region of MI heart (b), and peri-infarct region of MI ⫹NS heart (c). The reddish-brown staining demonstrates the presence of TGF-. Magnification ⫽ ⫻400. B: quantification of the effect of NS on TGF- immunostaining in sham (n ⫽ 6), MI/Cont (n ⫽ 9), and MI/NS hearts (n ⫽ 7). The difference between MI/NS and MI/vehicle was statistically significant (P ⬍ 0.05). COX-2 AND CARDIAC REMODELING cardiac function. COX-2 inhibition partly reverses these effects. Thus selective and timely use of COX-2 inhibitors may improve cardiac function after ischemic injury. ACKNOWLEDGMENTS The authors thank Dr. Yun-He Liu, Lisa Li, and Nicole Bart for assistance with morphometry. GRANTS This study was supported by National Heart, Lung, and Blood Institute Grant P01 HL-28982. REFERENCES AJP-Heart Circ Physiol • VOL 17. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, and Ross ME. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 98: 1294–1299, 2001. 18. Jugdutt BI, Hutchins GM, Bulkley BH, and Becker LC. Salvage of ischemic myocardium by ibuprofen during infarction in the conscious dog. Am J Cardiol 46: 74–82, 1980. 19. Koistinaho J and Chan PH. Spreading depression-induced cyclooxygenase-2 expression in the cortex. Neurochem Res 25: 645–651, 2000. 20. Lai J, Jin H, Yang R, Winer J, Li W, Yen R, King KL, Zeigler F, Ko A, Cheng J, Bunting S, and Paoni NF. Prostaglandin F2␣ induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am J Physiol Heart Circ Physiol 271: H2197–H2208, 1996. 21. Linssen MC, Engels W, Lemmens PJ, Heijnen VV, Van Bilsen M, Reneman RS, and van der Vusse GJ. Production of arachidonic acid metabolites in adult rat cardiac myocytes, endothelial cells, and fibroblastlike cells. Am J Physiol Heart Circ Physiol 264: H973–H982, 1993. 22. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, and Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99: 1926–1935, 1997. 23. Manabe I, Shindo T, and Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 91: 1103–1113, 2002. 24. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52: 5575–5589, 1992. 25. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, and Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91: 3228–3232, 1994. 26. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, and FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96: 272–277, 1999. 27. Mendez M and LaPointe MC. Trophic effects of the cyclooxygenase-2 product prostaglandin E2 in cardiac myocytes. Hypertension 39: 382–388, 2002. 28. Mukherjee D, Nissen SE, and Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954–959, 2001. 29. Mullane KM, Read N, Salmon JA, and Moncada S. Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs. J Pharmacol Exp Ther 228: 510–522, 1984. 30. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh S, and Kudo I. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275: 32783–32792, 2000. 31. Nagayama M, Niwa K, Nagayama T, Ross ME, and Iadecola C. The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 19: 1213–1219, 1999. 32. Noguchi K, Iwasaki K, and Ishikawa I. Prostaglandin F2 alpha upregulates intercellular adhesion molecule-1 expression in human gingival fibroblasts. J Periodontal Res 34: 277–281, 1999. 33. Ogawa T, Linz W, Stevenson M, Bruneau BG, Kuroski de Bold ML, Chen JH, Eid H, Scholkens BA, and de Bold AJ. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation 93: 2059–2067, 1996. 34. Oudot F, Grynberg A, and Sergiel JP. Eicosanoid synthesis in cardiomyocytes: influence of hypoxia, reoxygenation, and polyunsaturated fatty acids. Am J Physiol Heart Circ Physiol 268: H308–H315, 1995. 35. Palmer RM, Delday MI, McMillan DN, Noble BS, Bain P, and Maltin CA. Effects of the cyclo-oxygenase inhibitor, fenbufen, on clenbuterolinduced hypertrophy of cardiac and skeletal muscle of rats. Br J Pharmacol 101: 835–838, 1990. 36. Saito T, Rodger IW, Hu F, Shennib H, and Giaid A. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun 273: 772–775, 2000. 37. Sanchez PL, Salgado LM, Ferreri NR, and Escalante B. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension 34: 848–853, 1999. 286 • APRIL 2004 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.32.247 on May 10, 2017 1. Adams JW, Migita DS, Yu MK, Young R, Hellickson MS, CastroVargas FE, Domingo JD, Lee PH, Bui JS, and Henderson SA. Prostaglandin F2 alpha stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. J Biol Chem 271: 1179–1186, 1996. 2. Agha AM, El Khatib AS, and Al Zuhair H. Modulation of oxidant status by meloxicam in experimentally induced arthritis. Pharmacol Res 40: 385–392, 1999. 3. Bennett A and Villa G. Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Expert Opin Pharmacother 1: 277–286, 2000. 4. Bolli R, Goldstein RE, Davenport N, and Epstein SE. Influence of sulfinpyrazone and naproxen on infarct size in the dog. Am J Cardiol 47: 841–847, 1981. 5. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, and the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520–1530, 2000. 6. Bonow RO, Lipson LC, Sheehan FH, Capurro NL, Isner JM, Roberts WC, Goldstein RE, and Epstein SE. Lack of effect of aspirin on myocardial infarct size in the dog. Am J Cardiol 47: 258–264, 1981. 7. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, and Ruschitzka F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107: 405–409, 2003. 8. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, and Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62: 929–939, 2002. 9. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, and FitzGerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296: 539–541, 2002. 10. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, and Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability. Circulation 104: 921–927, 2001. 11. Domoki F, Veltkamp R, Thrikawala N, Robins G, Bari F, Louis TM, and Busija DW. Ischemia-reperfusion rapidly increases COX-2 expression in piglet cerebral arteries. Am J Physiol Heart Circ Physiol 277: H1207–H1214, 1999. 12. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, and Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 12: 1063–1073, 1998. 13. Harding P, Sigmon DH, Alfie ME, Huang PL, Fishman MC, Beierwaltes WH, and Carretero OA. Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet. Hypertension 29: 297– 302, 1997. 14. Harris RC. Cyclooxygenase-2 in the kidney. J Am Soc Nephrol 11: 2387–2394, 2000. 15. He Q, Wang D, Yang XP, Carretero OA, and LaPointe MC. Inducible regulation of the human BNP promoter in transgenic mice. Am J Physiol Heart Circ Physiol 280: H368–H376, 2001. 16. Hocherl K, Dreher F, Kurtz A, and Bucher M. Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure. Hypertension 40: 947–953, 2002. H1423 H1424 COX-2 AND CARDIAC REMODELING AJP-Heart Circ Physiol • VOL 45. Williams C, Shattuck-Brandt RL, and DuBois RN. The role of COX-2 in intestinal cancer. Ann NY Acad Sci 889: 72–83, 1999. 46. Williams CS, Mann M, and DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908–7916, 1999. 47. Wong SC, Fukuchi M, Melnyk P, Rodger I, and Giaid A. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation 98: 100–103, 1998. 48. Yamamoto T, Kakar NR, Vina ER, Johnson PE, and Bing RJ. Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ. Pharmacology 63: 28–33, 2001. 49. Yang F, Liu YH, Yang XP, Xu J, Kapke A, and Carretero OA. Myocardial infarction and cardiac remodelling in mice. Exp Physiol 87: 547–555, 2002. 50. Yang X, Ma N, Szabolcs MJ, Zhong J, Athan E, Sciacca RR, Michler RE, Anderson GD, Wiese JF, Leahy KM, Gregory S, and Cannon PJ. Upregulation of COX-2 during cardiac allograft rejection. Circulation 101: 430–438, 2000. 51. Yang XP, Liu YH, Mehta D, Cavasin MA, Shesely E, Xu J, Liu F, and Carretero OA. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B2 kinin receptor gene knockout mice. Circ Res 88: 1072–1079, 2001. 286 • APRIL 2004 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.32.247 on May 10, 2017 38. Scheuren N, Jacobs M, Ertl G, and Schorb W. Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured cardiac fibroblasts and role at acute myocardial infarction. J Mol Cell Cardiol 34: 29–37, 2002. 39. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A, and Bolli R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 97: 10197–10202, 2000. 40. Smith WL, DeWitt DL, and Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145–182, 2000. 41. Tardieu D, Jaeg JP, Deloly A, Corpet DE, Cadet J, and Petit CR. The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats. Carcinogenesis 21: 973–976, 2000. 42. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, and Burnett JC Jr. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91: 1127–1134, 2002. 43. Vane JR, Bakhle YS, and Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97–120, 1998. 44. Wang JL, Cheng HF, Shappell S, and Harris RC. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 57: 2334–2342, 2000.